Thomas S, O'Doherty M, Page C, Barlow D, Croft D, Bateman N; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 296 (abstract no. T.B.P.57).
St. Thomas' Hospital, London, UK
OBJECTIVE: To measure the absolute pulmonary deposition of two doses of pentamidine administered using two different nebuliser systems. METHODS: Following salbutamol pre-treatment, 8 patients with AIDS inhaled 50 and 150 mg pentamidine mixed with 37 MBq (0.05 mg) 99mTc human serum albumin (total volume 3 ml) via two nebuliser systems, System 22 Mizer (S22M, Medicaid UK) and Respigard (RII Marquest) using gas flow of 6 L/min. Pulmonary and non-pulmonary (oropharyngeal and gastric) deposition was measured using a gamma camera and absolute deposition calculated using a correction derived from lung phantom studies. Spirometry was measured before and after salbutamol and after pentamidine inhalation and adverse effects were recorded. RESULTS: Absolute pulmonary pentamidine deposition (mg+/- SEM) results are shown in the table: TABULAR DATA, SEE ABSTRACT VOLUME. S22M delivered more drug to the lungs and in a shorter time, with over 90% deposited within 10 min. RII produced less pulmonary and non-pulmonary deposition and fewer adverse effects. Inhalation of 150 mg pentamidine produced small reductions in FEV1 with both S22M (16.2%, p less than 0.01) and RII (7.5%, p less than 0.01). CONCLUSIONS: Pulmonary pentamidine deposition was greatest using S22M but RII was associated with fewer adverse effects.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Administration, Inhalation
- Albuterol
- Humans
- Lung
- Nebulizers and Vaporizers
- Pentamidine
- Technetium Tc 99m Aggregated Albumin
- United States
Other ID:
UI: 102177295
From Meeting Abstracts